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Abstract
The hemostatic properties of recombinant activated factor VII
(rFVIIa) are established in patients with inherited or acquired
hemophilia with inhibitors and in patients with congenital factor VII
deficiencies. Emerging clinical evidence suggests that there may
be a wider role for rFVIIa in the management of hemorrhage
associated with traumatic injury/accident and severe bleeding
associated with critical surgery. This article considers recent data
from studies in which rFVIIa was used in an attempt to control
bleeding in clinical situations as diverse as coagulopathy
associated with chronic liver disease, massive perioperative
bleeding and bleeding during prostatectomy, organ transplantation
and orthopedic surgery, uncontrollable obstetric hemorrhage, and
intracerebral hemorrhage. In nontrauma settings involving acute
and potentially life threatening bleeding, there may be a place for
rFVIIa as adjunctive therapy in the control of hemostasis.
Introduction
Since the first reports of hemostatic responses in trauma
patients with uncontrolled hemorrhage [1,2], a growing body
of literature has addressed the use of recombinant activated
factor VII (rFVIIa – NovoSeven®; Novo Nordisk A/S,
Bagsværd, Denmark) in settings outside the therapy of
hemophilia patients with high titer inhibitors. Several articles
(e.g. Hedner and coworkers [3], Roberts and colleagues [4],
and other reviews in this supplement) have described the
developmental background of this agent, highlighted its
mechanism of action, and reviewed its use in a variety of
clinical settings, including qualitative and quantitative
thrombocytopenic conditions, liver disease, and acquired
surgical and medical bleeding conditions in patients with
presumed intact hemostatic mechanisms. This literature, along
with what appears to be an acceptable early toxicity profile
and a putative mechanism of action that involves increased
thrombin generation at sites of vascular injury in concert with
activated platelets, has pointed toward consideration of the
wider use of rFVIIa as a hemostatic agent. However, as in the
setting of acute trauma, significant issues of cost, indications,
laboratory monitoring, safety, optimal dose, and use with blood
products and other hemostatic agents remain to be
established for rFVIIa use in patients without acute trauma
who do not have hemophilia. In this report we review these
issues for clinical conditions that are likely to be encountered
in the operating theatre or intensive care unit.
Hematologic disease (platelet and
coagulation factor defects)
Treatment of spontaneous bleeding in patients with
hemophilia types A and B who have developed inhibitors to
factors VIII and IX, respectively, remains the only indication
approved by the Food and Drug Administration for the use of
rFVIIa in the USA [5]. In the European Union this treatment is
indicated in the setting of surgical bleeds in hemophilia types
A and B with inhibitors against factors VIII and IX,
respectively; in patients with acquired hemophilia; in patients
with congenital factor VII deficiency undergoing surgery or
invasive procedures; and in patients with Glanzmann’s
thrombasthenia. Response rates have been excellent in these
patients, in settings ranging from major to home treatment of
bleeding episodes. The dose recommended in the package
insert (90 µg/kg) is given as an intravenous bolus every
2–3 hours until the bleeding stops. Higher doses are favored
by some investigators, and the agent has been safely used in
patients receiving concomitant antifibrinolytic agents [6].
Patients with decreased levels of factors VII and XI have
successfully been treated with rFVIIa. In factor VII deficient
patients doses of 15–20 µg/kg have been given every
2–3 hours, whereas in factor XI deficiency therapeutic doses
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of rFVIIa range from 90 to 120 µg/kg, given in a similar
schedule [7,8]. As in the hemophilia setting, rFVIIa may also
be useful in patients with von Willebrand’s disease who have
developed antibodies against von Willebrand factor or who
fail to respond to conventional therapy [9,10]. Finally, rFVIIa
was reported in anecdotal studies to be successful in treating
patients with both qualitative and quantitative platelet defects
[5]. Because of the complexity involved in diagnosing these
disorders, and because of considerations of alternative
therapies, treatment of these patients is best undertaken in
collaboration with a hematologist specializing in such cases.
Based on the mechanism of action, rFVIIa is unlikely to be
effective in patients with zero levels of factor X or with severe
thrombocytopenia (counts <5000/µl).
The use of rFVIIa in patients with bleeding and complex
hematologic disturbances was highlighted in a recent study
(reported in abstract form) conducted in patients with severe
bleeding complications following hematopoietic stem cell
transplantation (HSCT) [11]. In a double blind design
comparing placebo and three different doses of rFVIIa (40,
80, and 160 µg/kg), 100 patients with moderate or severe
bleeding (lower and upper gastrointestinal tract, hemorrhagic
cystitis, pulmonary, intracerebral, and other sites) that
occurred 2–180 days after HSCT were treated every 6 hours
for 36 hours. Patients who received the intermediate rFVIIa
dose of 80 µg/kg were reported to exhibit significant improve-
ments in bleeding status from 0 to 38 hours as compared
with standard hemostatic treatment (P = 0.021). However,
patients who received the other two doses did not improve
compared with the placebo patients. Patients were excluded
from the study if they had recent thromboembolic events,
atherosclerotic disease, disseminated intravascular coagulation
(DIC), thrombotic microangiopathy, veno-occlusive disease,
or active leukemia (acute mylogenous leukaemia types M3,
M4, M5). Further studies are needed to establish optimal and
effective dose regimens for rFVIIa in heterogeneous patient
populations such as those experiencing bleeding after HSCT.
Liver disease and gastrointestinal bleeding
Orthotopic liver transplantation
Orthotopic liver transplantation (OLT) is commonly associated
with excessive blood loss and need for considerable
transfusion of blood and blood products. Blood loss may
result from surgical causes as well as impaired hemostasis
caused by decreased concentrations of coagulation factors,
hyperfibrinolysis, and thrombocytopenia. One of the most
serious complications of liver transplantation is hepatic artery
thrombosis; thus, any measure to improve hemostasis should
not increase the risk for thrombosis.
A recent open label, dose finding study conducted by
Hendriks and colleagues [12] showed that rFVIIa reduced
transfusion requirements in patients undergoing OLT
because of chronic end-stage liver disease (Child-Turcotte
[Pugh’s modification] score B or C). Following an intravenous
injection of 80 µg/kg rFVIIa 10 min before the start of surgery,
there was a significant reduction in transfusion requirements
(both allogenic and autologous) and blood loss between
treated patients and control individuals (3.5 l [range
1.4–5.3 l] in treated patients versus 9.8 l [3.7–35 l] in control
individuals;  P = 0.004). However, only six patients were
treated with rFVIIa and, of particular concern, the 12 control
individuals were previously treated patients whose records
were obtained from the hospital database. There were no
thrombotic complications. Similar results were observed in a
more recent, but again uncontrolled study [13] in which
patients received a single bolus dose of rFVIIa (68.37 µg/kg
body mass [range 32.88–71.84 µg/kg]) intravenously 10 min
before skin incision, without any thrombotic complications.
Two larger scale, double blind studies in patients undergoing
OLT also support the efficacy of a single dose of rFVIIa in
reducing patient requirements for transfusion products,
without any increase in the incidence of thromboembolic
complications [14,15]. Planinsic [15] randomly assigned 83
patients, undergoing OLT for end-stage liver disease, to
treatment with placebo or a single bolus dose of 20, 40, or
80 µg/kg rFVIIa given 10 min before surgery. In this study,
treatment with 80 µg/kg rFVIIa was associated with a
significant reduction in requirement for fresh frozen plasma
(FFP). A larger study, involving 182 OLT patients, compared
the efficacy and safety of doses of 60 µg/kg and 120 µg/kg
rFVIIa 10 min before skin incision, followed by repeat dosing
every 2 hours until 30 min before the expected start of
reperfusion of the transplanted liver [14]. This study assessed
the volume of blood products transfused and blood loss
during the perisurgical period and for 24 hours after surgery.
Within the group of 179 patients who completed the
observation period, a significantly higher number of patients
receiving rFVIIa avoided red blood cell (RBC) transfusion,
with 10% (6/62 patients) avoiding transfusion in the
60 µg/kg group, 7% (4/56) in the 120 µg/kg group, and no
avoidances (0/61) in the placebo group (P < 0.03).
Partial hepatectomy
The hemostatic efficacy and safety of rFVIIa for the prevention
of bleeding episodes in noncirrhotic patients undergoing partial
hepatectomy were evaluated in a multicenter, double blind,
placebo controlled study involving 204 patients [16]. Patients
were randomly assigned to receive either 20 or 80 µg/kg rFVIIa
or placebo 5 min before the first skin cut and any clamping
procedures, with a second identical dose given 5 hours after
first skin cut if time in surgery was anticipated to extend beyond
6 hours. Perioperative RBC transfusion requirements and
blood loss were assessed, and safety of therapy was evaluated
by means of laboratory monitoring of coagulation parameters
and Doppler examination of hepatic vessels and lower
extremities for any signs of thromboembolism.
This study found that only 25% of patients treated with
80 µg/kg rFVIIa required transfusion whereas 37% ofS31
placebo patients and 41% of patients receiving 20 µg/kg
rFVIIa required transfusion [16]. Although there were no
significant differences between the treatment groups in
terms of mean erythrocyte requirement in patients receiving
erythrocytes (1024 ml for placebo group, 1354 ml for the
20 µg/kg rFVIIa group, and 1036 ml for the 80 µg/kg rFVIIa
group) and no differences in intraoperative blood loss, the
reduction in hematocrit during surgery was smallest in the
80 µg/kg rFVIIa group, with a significant overall effect of
treatment (P = 0.04). Thromboembolic events were
observed at a similar rate in all three treatment groups. The
study investigators concluded that rFVIIa dosing did not
reduce, to a statistically significant extent, either the number
of patients transfused or the volume of blood products
administered.
Liver biopsy
Patients with acute or chronic liver disease may develop a
complex coagulopathy including various degrees of thrombo-
cytopenia; a prolonged prothrombin time (PT) due to
decreased levels of coagulation factors; and hyperfibrinolysis,
which complicates performance of common surgical and
medical procedures including dental extraction and liver
biopsy [17,18]. Treatment of such patients with FFP or
prothrombin complex concentrates may be associated with
possible virus transmission, variable effectiveness, and
volume overload [19]. Studies conducted in warfarin treated
rats and in healthy human volunteers pretreated with
anticoagulants [20,21] have suggested that rFVIIa may
enhance hemostasis in situations that mimic the coagulation
defects seen in chronic severe liver disease.
In a pilot study of patients who did not undergo invasive
procedures [22], rFVIIa was given to 10 cirrhotic patients at
increasing doses of 5, 20, and 80 µg/kg. The rFVIIa was
successively administered at weekly intervals beginning
10 days after initial failure to respond to vitamin K injection.
The PT corrected to normal or near normal levels for all
doses; more prolonged responses occurred after the higher
doses, and there were no episodes of disseminated intra-
vascular coagulation (DIC).
In a blinded, randomized study of rFVIIa dosed at 5, 20, 80,
and 120 µg/kg in cirrhotic patients undergoing biopsy [23],
a maximum reduction in PT values was observed 30 min
after dosing. Furthermore, patients treated with 80 and
120 µg/kg exhibited significantly longer duration of
normalization of the PT. Hemostasis, assessed by direct
visualization via laparascopic biopsy, was achieved within
10 min in 74% of patients evaluated, but there was no effect
attributable to treatment dose. The low volumes of rFVIIa
used in these studies and the lack of viral transmission
associated with this agent indicate that infectious
complications and volume overload should be reduced.
Further studies are indicated to determine the risk for
thrombosis or DIC.
Gastrointestinal bleeding and cirrhosis
A number of pilot studies suggested that rFVIIa could
normalize PTs and might therefore improve hemostasis in
patients with cirrhosis and esophageal variceal bleeding
associated with abnormal clotting [22,24]. However, the
promise of these initial anecdotal reports was not supported
in a large recent study [25] in which 245 cirrhotic patients
with upper gastrointestinal bleeding were randomly assigned,
in a double blind manner, to receive eight doses of placebo
versus 100 µg/kg rFVIIa at the start of the study and at 2, 4,
6, 12, 18, 24, and 30 hours thereafter. Blood transfusion was
given to maintain the hematocrit between 25% and 30%, and
patients were treated according to common guidelines for
endoscopy (sclerotherapy and banding) and use of vaso-
active treatment (terlipressin, somatostatin, or octreotide).
The two study groups were similar in terms of baseline
demographic data.
No significant differences were observed in thromboembolic
events or mortality, which tended to be slightly smaller in the
placebo group than in the treatment group (4/119 versus
7/118 at 5 days and 11/119 versus 16/116 at 42 days) [25].
In a small group of patients with severe esophageal bleeding
(variceal bleeders of Child-Turcotte [Pugh’s modification]
score B or C) there was a marked reduction in bleeding, and
control of bleeding was improved. The authors therefore
concluded that further studies are warranted to determine
which patient groups may benefit from use of rFVIIa.
Reversal of coumadin overdose
Review of the available literature suggests that rFVIIa is
efficacious in the reversal of anticoagulant treatment with
vitamin K antagonists [26]. Studies have shown that single
doses of rFVIIa can normalize international normalized ratio
(INR) and PT in healthy volunteers given acenocoumarol
treatment at anticoagulant doses. In a group of volunteers
pretreated with acenocoumarol, INR was elevated to above 2,
factor X and factor IX levels were reduced by 19–46%,
protein C levels were reduced by 2–20%, and factor VII
levels were reduced by 4–17%. A single dose of 5 µg/kg
rFVIIa normalized INR within 12 hours, whereas doses of
rFVIIa of above 120 µg/kg were found to correct INR for
periods of 24 hours without signs of systemic coagulation.
The ability of rFVIIa to effect rapid reversal of oral
anticoagulation in clinical settings has been reported in an
uncontrolled case series including patients with an array of
comorbid conditions requiring anticoagulant therapy for
prevention and management of venous thromboembolism
and cardiovascular or cerebrovascular occlusions [27]. In all
13 cases, patients had critically increased INRs requiring
immediate reversal of warfarin induced anticoagulation. In five
cases the INR was above 10, in four cases patients were
deemed to be at risk for clinical hemorrhage, and in four
cases the patient required diagnostic or therapeutic inter-
ventions involving bleeding risk. The use of rFVIIa at doses
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ranging from 15 to 90 µg/kg was associated with rapid and
effective correction of prolonged INRs and aversion or
reversal of bleeding due to warfarin toxicity; the authors felt
that lower doses were as efficacious as the higher doses
used in the study. Furthermore because the duration of
response to rFVIIa is shorter than the anticoagulant effect of
oral agents, patients should be closely followed clinically and
carefully monitored after treatment. These patients may also
require vitamin K therapy for more long term control of
hemostasis.
Surgery and massive transfusion in patients
with normal and abnormal preoperative
hemostasis
Prostatectomy
Abdominal retropubic prostatectomy is often associated with
considerable perioperative blood loss [28]. Friederich and
colleagues [29] investigated the prophylactic use of rFVIIa in
patients undergoing this operation in a small, double blind
study comparing placebo (12 patients) with two different
doses rFVIIa (20 µg/kg [eight patients] and 40 µg/kg [16
patients]). The results revealed a dose dependent, significant
reduction in perioperative blood loss (1235 ml and 1089 ml in
the 20 and 40 µg/kg groups, respectively, versus 2688 ml in
the placebo group; P = 0.001) and reduced operating room
time for treated patients compared with placebo. No patients
in the 40 µg/kg group received any transfusions, whereas
more than half of the patients in the placebo group required
allogenic RBC transfusion. Although the blood loss in the
control group appeared to be higher than some centers
consider to be the standard, this study remains one of the few
randomized, double blind, placebo controlled studies of the
use of rFVIIa in patients with normal preoperative hemostasis.
Cardiac surgery
There have been a number of case reports of the use of
rFVIIa in patients undergoing various forms of cardiac surgery
[30-34]. The use of rFVIIa thus far has usually followed
cardiac surgery (valve replacement or bypass grafting) and
usually involves the successful use of the agent to help
terminate profound postoperative hemorrhage. Although it is
intriguing that rFVIIa appears to have been successfully used
in a small number of patients without graft thrombosis, to
date there have been no placebo controlled studies of the
use of rFVIIa in cardiac surgery.
Neurosurgery
There have been two reports of the use of rFVIIa in
neurosurgical patients [35,36]. The first [35] reported on the
successful use of rFVIIa in a patient with a large recurrent
skull base hemaniopericytoma with difficult intraoperative
hemostasis. The second report [36] described the use of
rFVIIa in nine patients with a variety of different neurosurgical
conditions who also had a coagulopathy before surgery. All
patients were treated preoperatively with rFVIIa to correct the
coagulopathy before surgery. In all cases the use of rFVIIa
was successful, and none of the patients developed any
procedure related complications.
Orthopedic surgery
In a randomized, controlled, double blind study, Raobaikady
and coworkers [37] investigated the prophylactic use of
rFVIIa in a group of patients undergoing semielective open
reduction on traumatic pelvic and pelvic acetabular fractures.
Historically, this group of patients had a mean blood loss of
approximately 2.5 l (similar to the blood loss observed in the
prostatectomy study conducted by Friederich and
colleagues [29]). Patients were randomly assigned to
receive 90 µg/kg of either placebo or rFVIIa immediately
after skin incision. Based on the results of the study by
Friederich and colleagues, it was expected that this would
result in at least a 50% reduction in measured blood loss
and a reduction in the need for blood transfusion. The
measured blood loss in patients receiving rFVIIa was found
to be greater than in patients receiving placebo (2070 ml
versus 1535 ml). However, when the total blood loss at
48 hours after the start of surgery was also calculated using
the method described by Rosencher and coworkers [38],
the group receiving rFVIIa had less blood loss (2146 ml
versus 2787 ml), although this difference was not
statistically significant. It was also noted that a greater
number of patients in the placebo group than in the treated
group received allogenic blood components (67% versus
46%), but again this difference was not statistically
significant. The authors concluded that the prophylactic use
of rFVIIa was not justified in fit healthy patients, with normal
clotting systems, undergoing major surgery unless there are
special circumstances to warrant its use.
Gynecological/obstetric surgery
A case report by Danilos and colleagues [39] described the
successful use of rFVIIa (single 80 µg/kg dose) in a patient
who underwent a total abdominal hysterectomy with salpingo-
oophorectomy and developed postoperative hemorrhage
5 hours after apparently successful initial surgery.
Bouwmeester and coworkers [40] described a patient with a
massive 42 unit packed RBC transfusion postpartum who
responded within 10 min of receiving a single dose of
60 µg/kg rFVIIa.
Other case reports of use of rFVIIa for management of life
threatening postpartum hemorrhage include the case of a
patient with rapid onset pre-eclampsia requiring delivery via
cesarian section who had a deranged coagulation profile,
which persisted despite attempts to stem surgical bleeding
and correct coagulopathy by transfusion of RBC and blood
products [41]. A single dose of rFVIIa 90 µg/kg was found to
effect a rapid clinical response, which was evident within
30 min, reducing abdominal drainage within 3 hours such that
the patient had no further requirement for RBC transfusion
and gradually returned to a normal coagulation profile and
platelet count by day 10 after admission.
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Ahonen and Jokela [42] recently reported their experience of
using rFVIIa in 12 cases of severe postpartum hemorrhage. In
11 cases there was partial or good response to treatment
when it was applied after conventional medical and surgical
intervention had failed to correct bleeding. These authors
suggest that in cases of intractable obstetric bleeding, where
there is no other obvious case for hysterectomy, rFVIIa should
be considered before resort to radical surgery.
Kidney transplantation
Recombinant activated factor VIIa has been evaluated for its
ability to effect hemostasis in a patient admitted to an intensive
care unit following his third kidney transplant [43]. The patient
had end-stage renal failure caused by mesangiocapillary
glomerulonephritis and had been dialysis dependent for
25 years. The postoperative recovery period was complicated
by hemodynamic instability and myocardial infarction. Three
days after his transplant the patient bled and developed a
large perinephric hematoma. He was returned to the operating
theatre but no obvious cause for bleeding was found. He was
transfused further but was again returned to theatre after more
bleeding. He was finally given 70 µg/kg rFVIIa and the
bleeding stopped. This use of rFVIIa was despite the patient
having recently suffered a myocardial infarction.
Massive transfusion associated with surgery and
medical conditions
O’Connell and colleagues [44] described a series of 40
patients who developed massive bleeding that was
unresponsive to conventional therapy. These authors reported
a series of patients collected from 13 hospitals. The patients
described were predominantly patients undergoing surgery,
although 10 were medical patients. Only two patients in their
series had a history of trauma. The median number of doses of
rFVIIa used was two (range 1–18), and the individual doses
varied in the range 15–180 µg/kg. Only two patients received
more than four doses of rFVIIa. A total of 80% of patients
achieved a complete or partial cessation of bleeding after
administration of rFVIIa. Eighteen patients stopped bleeding
completely and in 14 cases the bleeding slowed significantly.
Eight patients (20%) did not achieve hemostasis after
administration of rFVIIa. Six of these eight patients had liver
disease, and the remaining two had undergone emergency
repair of ruptured abdominal aortic aneurysm.
There was no evidence of a dose response, either in patients
who achieved hemostasis or in the three cases with
thromboembolic complications: hepatic artery thrombosis
following transplantation; iliac vein thrombosis following iliac
artery and vein manipulation during repair of a postradiotherapy
fistula in a patient with bladder cancer; and multiple pulmonary
emboli found at autopsy in a patient with disseminated
lymphoma, who developed multiorgan system failure following
surgery for intractable gastrointestinal bleeding. Of note,
antifibrinolytic agents were used in conjunction with rFVIIa in a
considerable number of cases, which is consistent with other
anecdotal reports of the successful use of tranexamic acid in
conjunction with rFVIIa in hemophilia [45].
Intracerebral hemorrhage
Intracerebral hemorrhage (ICH) accounts for between 10%
and 30% of strokes and is associated with high mortality and
morbidity. It is known that the volume of bleed into the brain is
a major predictor of neurological and functional outcome after
ICH, and interest in a clinical role for rFVIIa in stroke
management has been fueled by recent reports showing that
this treatment has a good safety profile in patients with acute
ICH and appears to be effective in reducing hemorrhage
growth, with resultant improvements in clinical outcome for
patients [46,47].
A double blind, placebo controlled study in patients with
acute ICH [47] compared the effects of treatment with
40 µg/kg (108 patients), 80 µg/kg (92 patients), or
160 µg/kg (103 patients) of rFVIIa versus placebo (96
patients) on hemorrhage growth, deaths, and functional
outcome at 3 months. Treatment was given within 1 hour of a
diagnostic computed tomography scan. Compared with a
29% growth in placebo treated patients, ICH volume growths
at 24 hours in the 40, 80, and 160 µg/kg rFVIIa treatment
groups were 16%, 14%, and 11%, respectively. In terms of
reduction in hematoma growth, this reflected 3.3 ml, 4.5 ml,
and 5.8 ml reductions, respectively, for the three treatment
groups versus placebo. Pooled data for all doses of rFVIIa
showed that treatment resulted in a 52% relative reduction in
hemorrhage growth compared with placebo (P = 0.01).
There was a mean increase in hemorrhage volume of 8.7 ml
in the placebo group, but the mean increase in patients
receiving rFVIIa (all doses combined) was 4.2 ml. Treatment
with rFVIIa was associated with a significant increase in
numbers of patients with an improved clinical outcome. Three
months after ICH it was found that acute rFVIIa treatment
effected an absolute reduction in risk for death or severe
disability of 16% (death/disability: 69% placebo versus 53%
for all doses of rFVIIa combined; P = 0.004, all doses versus
placebo), and it was shown that treatment with rFVIIa more
than doubled a patient’s chances of improving one level on
the modified Rankin Scale. There was a 38% relative
reduction in patient mortality at 3 months (29% for placebo
versus 18% for all doses of rFVIIa; P = 0.02). However, in
this study serious thromboembolic events such as
myocardial infarction and cerebral infarction occurred in 7%
of rFVIIa-treated patients, as compared with 2% of placebo
treated patients (P < 0.05) and the exclusion criteria were
changed midway through the trial, because of concerns
about safety, to exclude patients with a history of
thromboembolic disease [47].
Optimal dose, monitoring and concurrent use
of blood products
As described in this review, rFVIIa has been used in a range
of nontrauma settings and employed at a wide range of
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doses for management of hemorrhage that fails to respond to
conventional medical and surgical management. The variation
in selected doses reflects the history of investigation of this
therapy outside the hemophilia setting, in which there was
often uncertainty regarding the dose required for optimal
hemostatic efficacy, tempered by early concerns that this
treatment could have thrombogenic potential.
Given the mechanism of action of rFVIIa, there was concern
that activation of tissue factor at sites such as atheromatous
plaques in patients with ischemic heart disease might
precipitate clinically relevant coagulation and thrombosis.
However, time and experience suggest that initial worries of
severe, widespread thrombosis were slightly alarmist, and
more recent studies have tended to use rather larger doses.
This has culminated in the study conducted by Boffard and
coworkers [48] in blunt and penetrating trauma, in which
investigators used a large initial dose of 200 µg/kg followed
by two further doses of 100 µg/kg in an attempt to manage
bleeding in patients with traumatic bleeding requiring
transfusion of 8 units of RBCs before administration of rFVIIa.
The rationale for selecting this large dose was that it would
provide serum concentrations of rFVIIa that Hedner and her
colleagues felt from animal studies would be required to
ensure (maintain) maximal coagulation from the effect of
rFVIIa [3]. Further studies may determine whether more
judicious use of rFVIIa is appropriate. An investigation into
rFVIIa in prostatectomy [29] found good results with just
20 µg/kg and very good results with 40 µg/kg, and many of
the case reports describe good results with around
80–90 µg/kg – the sort of dose used in management of
hemophillia. It would seem prudent at this stage, until more
safety studies have been completed, to consider doses in the
range 40–80 µg/kg; the lower dose may be increased if
appropriate in many acute use settings where there is no
definitive body of evidence to direct practice.
A number of practical issues arise when using rFVIIa in acute
management of hemorrhage, such as wastage of product
once vials are opened, difficulties and/or unavailability of
blood bank supplies, and inability to optimize all acute
patients to achieve an ideal coagulation profile before
administration of rFVIIa. Therefore some transfusion services
have developed recommendations for rFVIIa based on the
clinical condition, utilizing vial based dosing algorithms [49],
such as the use of a 1200 µg vial and follow up with vitamin
K therapy in cases involving prolonged INR with minimal
bleeding or a 4800 µg vial for uncontrollable hemorrhage, in
50 to 100 kg adult patients unresponsive to more standard
initial therapy [49]. In addition, rFVIIa may be useful in
patients who urgently require FFP but have clinically
documented significant IgA deficiency, in severely HLA-
alloimunized thrombocytopenic patients who lack commonly
available donors or in patients with rare RBC types or with
multiple red cell alloantibodies who are undergoing surgery
and other invasive procedures, in whom standard blood
product transfusion may be ineffective or dangerous. In these
cases, practicality and cost profiles change, and treatment
may be necessary in the absence of the usual standard
therapies. 
Safety profile
Clinical experience with rFVIIa suggests that this treatment
has a safety profile that favors overall efficacy in a variety of
clinical settings. However, any concerns about use of the
product should be addressed whenever possible during
consultation with a hematologist. Few patients would be
expected to experience allergic reactions to the components
of rFVIIa, and through laboratory monitoring and close
assessment of patients it should be possible to identify cases
and signs of any resultant adverse events during use of this
treatment. The most appropriate form of monitoring of rFVIIa
is a topic of continued debate (see the review by Pusateri
and Park in this supplement), because some laboratory
measures of rFVIIa activity have not been found to correlate
closely with clinical outcomes, and therefore often serve as a
guide as to whether treatment has indeed been effectively
dosed or are used to provide some insight into whether
coagulopathies are indeed responsive to rFVIIa therapy.
Thromboelastography may offer insights and correlate with
rFVIIa effects [50] and has been used in clinical studies in
which liver transplant patients were given rFVIIa [51].
Although patients with DIC have been excluded from receiving
rFVIIa in prior studies, rFVIIa was recently specifically used in
patients with DIC and associated hemorrhagic episodes. In
this setting it was found to be effective in normalizing PT and
activated partial thromboplastin time, and in controlling
bleeding, without causing thromboemolic complications [52].
In a study of 18 patients with malignancy and bleeding
secondary to DIC, administration of 3–10 doses of rFVIIa
90 µg/kg was effective hemostatic treatment, which the
authors suggest are encouraging results, supporting the
cautious use of rFVIIa in hemorrhagic DIC patients who fail to
respond to conventional therapy. Despite the promise of this
initial study, current best practice should involve very cautious
use of this agent in DIC, active thrombosis, vascular grafts
with endothelial injury, or other conditions at risk for
thrombotic sequelae.
Conclusion
A growing body of evidence suggests that there is a role for
rFVIIa in the management of acute, nontraumatic hemorrhage
associated with a wide variety of clinical conditions in cases
where bleeding cannot be controlled by conventional medical
and surgical means. The ultimate safety, and the most
appropriate and effective dose to employ in different patient
groups are not well established. At present there is a large
number of anecdotal case reports but only a few randomized,
double blind, placebo controlled studies to provide evidence
of this agent’s efficacy outside its licensed indications. A
number of studies have not demonstrated significant efficacy,
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and there is a need for large scale safety studies to ensure
that thromboembolic events do not become a major cause of
morbidity. However, through close consultation with a
hematologist, it should be possible to determine which
patients might benefit from this hemostatic agent, and – as
clinical studies with rFVIIa continue to report – the value of
this treatment in both trauma and nontrauma settings will be
established.
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